Let’s start with the most important point: If a senior’s shoulder repeatedly swells with fluid, and you can draw out a large bottle every time, it’s mostly not “simple degeneration,” but another disease.

This post is for you if you have an older family member whose shoulder repeatedly fills with fluid, has been aspirated several times, but always swells up again quickly.

What is this disease?

Inside the shoulder is a group of tendons called the “rotator cuff,” which is responsible for hanging the arm steadily in the shoulder socket. As we age, this tendon group can tear completely. After it tears, the humeral head moves upward, and bone rubs directly against bone. The fine calcium salt crystals ground off fall into the joint cavity, which in turn stimulates the joint lining to inflame and continue the destruction.

This condition has a name: Milwaukee shoulder. Some also call it “cuff tear arthropathy.”

Three typical signs

  • Mostly older women, and 60% of people have it in both shoulders
  • The aspirated joint fluid is large in volume, and often blood-tinged
  • X-rays look different from general osteoarthritis: very few bone spurs, but severe destruction

Why does the fluid come back after being aspirated?

This is the most frustrating part for many families: we just aspirated it last week, and it’s swollen again this week.

The reason is, the fluid is not the “cause” of this disease, but the “result”. The underlying tendon tear and bone wear are still there, so the joint will keep producing fluid. So the purpose of aspirating is to make the senior comfortable and allow the arm to move, not that drying it out will cure it.

Understanding this makes you feel a lot better, and you’re less likely to think “did the doctor fail to cure it?”.

What else can be done when aspirating?

If the doctor recommends aspiration, that bottle of fluid drawn out is actually very useful. It can be sent for testing:

  • To see if there’s a bacterial infection: This is the most important one. Infection looks very similar to this disease, but the management is completely different
  • To see what kind of crystals are there: Different crystals mean different diseases (gout, pseudogout, or this one)
  • To check the cell count: To distinguish whether it’s “inflammatory” or “non-inflammatory”

Can seniors with bad kidneys get steroid injections?

This is a question I get asked a lot. The short answer is: Yes, they can, and there’s no need to reduce the dose because of poor kidney function.

However, there are two things to confirm with the doctor:

What to watch out for before and after the injection

  • You must rule out infection before injecting. This is the only situation where you really can’t inject
  • For seniors with diabetes, blood sugar will rise within a week after the injection. You might need to let the internal medicine doctor know to temporarily adjust medications

As for “whether steroids damage the kidneys,” steroids are mainly metabolized by the liver and don’t directly damage the kidneys. What to watch out for is that it makes the body retain water and salt. For seniors with poor kidney function, it’s easier to get edema and higher blood pressure, so after the injection, watch if their feet are swollen and if their blood pressure has gone up.

Conversely, exactly because people with bad kidneys aren’t suitable for long-term painkillers, joint injections actually become a relatively safe option.

When should surgery be considered?

If all conservative treatments have been tried, the shoulder still hurts a lot, the arm can’t be lifted, and daily life is affected, you can ask orthopedics to evaluate for a “reverse total shoulder arthroplasty.” This is a surgery specifically designed for shoulders where the rotator cuff has already torn.

—

Further reading: Cross-textbook automated notes production workflow (How these notes were made)

Below is the original form of this note in my vault, with only the internal links and copyrighted textbook images removed. The verification process and tool descriptions are at the end.

Clinical Pearls

  • Older women + recurrent massive blood-tinged shoulder effusions + very few bone spurs on imaging → think Milwaukee shoulder, not primary GH OA (Kelley Ch.102)
  • Three core elements: massive rotator cuff tear + intra-articular BCP crystals + rapid GH joint destruction (ElMiedany Ch.7)
  • Synovial fluid is non-inflammatory (low mononuclear cell count) but often blood-tinged; BCP is nonbirefringent and cannot be seen under polarized light microscopy, needs alizarin red S staining (Kelley Ch.56)
  • 60% bilateral, 50% simultaneous knee joint involvement (Kelley Ch.105)
  • Mainstay of treatment = repeated aspiration + local steroid injection; but you must rule out infection before injecting (Martinoli Ch.6, Kelley Ch.102)

Background

Definition

  • Milwaukee shoulder syndrome (MSS) = massive rotator cuff tear combined with intra-articular BCP crystal deposition, causing rapid destructive arthropathy of the GH joint (ElMiedany Ch.7)
  • Synonyms: cuff tear arthropathy, apatite-associated destructive arthritis, hemorrhagic shoulder, rapid destructive arthritis of the shoulder (Martinoli Ch.6, Kelley Ch.102)
  • History of nomenclature
    • Adams described this pathological change in 1873 (Kelley Ch.49)
    • McCarty named it “Milwaukee shoulder” (Kelley Ch.49, McCarty 1989)

Epidemiology

  • A rare destructive arthropathy of the GH joint (Kelley Ch.105)
  • Predominantly affects older individuals, mainly women (Kelley Ch.102, Martinoli Ch.6)
  • 60% are bilateral; 50% simultaneously involve the knee joint (Kelley Ch.105)
  • Can be bilateral but the dominant side is usually more severe (Kelley Ch.102)
  • The shoulder joint is the most common joint region affected by symptomatic BCP crystal deposition, related to the special structural function of the shoulder (Kelley Ch.102)
  • Knees and hips can also present with MSS-like lesions, which can appear in the same person as shoulder lesions (Kelley Ch.102)
    • Unlike primary OA, BCP-related destructive knee lesions often involve the lateral tibiofemoral compartment (Kelley Ch.102)

Mechanism

  • Mainstream model: Mechanical instability caused by a rotator cuff tear is the driving force (Kelley Ch.102)
    • Bone fragments release BCP crystals into the joint cavity
    • Secondary synovitis and connective tissue destruction
  • Synovial fluid biochemical abnormalities
    • Contains microspheroids, with hydroxyapatite crystals, active collagenase, and neutral protease inside (Garancis 1981)
    • Elevated 5-nucleotidase activity (Kelley Ch.49, Wortmann 1991)
    • Elevated inorganic pyrophosphate (PPi) and nucleotide pyrophosphohydrolase activity (Kelley Ch.49, Kelley Ch.102)
  • Triggers / comorbidities (actively look for these clinically) (Kelley Ch.49, Kelley Ch.102)
    • Coexisting CPPD crystal deposition
    • Direct trauma, chronic joint overuse
    • Chronic renal failure (especially those on dialysis)
    • Denervation / neuropathic factors
    • Mechanical abnormalities
  • Aging itself is a factor for BCP crystal deposition in articular cartilage (Kelley Ch.102)

Special attention for the CKD population

Symptomatic articular and periarticular BCP crystal deposition mostly occurs in advanced chronic renal failure, especially dialysis patients; it can be destructive and involve the axial skeleton. This population might also have coexisting CPPD or oxalate crystal deposition (Kelley Ch.102). Secondary hyperparathyroidism can also contribute to BCP-related arthropathy and calcific bursitis (Kelley Ch.102).

Complications

  • Shoulder joint capsule rupture, with blood-tinged synovial fluid seeping into the periarticular soft tissue, which can last for weeks to months (Martinoli Ch.6)
    • Clinically presents as diffuse shoulder swelling with ecchymosis (Martinoli Ch.6)
  • Formation of pseudoarthrosis between the humeral head, coracoid, and acromion (Martinoli Ch.6)
  • Cartilage destruction and subchondral bone osteolysis (Martinoli Ch.6)
  • Secondary degenerative changes, even osteonecrosis of the humeral head (Kelley Ch.49)

Prognosis

  • Disease course is rapidly progressive destructive arthritis, accompanied by pain, swelling, limited range of motion, and joint instability (Martinoli Ch.6)
  • Patients with massive rotator cuff tears mostly remain stable and rarely require treatment; the difficulty lies in predicting who will progress to cuff tear arthropathy (Kelley Ch.49)
    • Those with massive cuff tears and local CPPD might be more prone to further humeral head upward migration and joint destruction (Kelley Ch.49)
  • Reason treatment is tricky: Bone erosion and cuff rupture compromise the functional outcomes of an unconstrained prosthesis (Kelley Ch.49)

Evaluation

Diagnostic Criteria

  • Currently no consensus clinical diagnostic criteria (true for all articular BCP crystal deposition diseases); it is a clinical diagnosis (Kelley Ch.102)
  • Diagnosis is established via one of two pathways (Kelley Ch.102)
    • Characteristic calcification of BCP crystals detected on imaging
    • Confirmation of BCP crystals by transmission electron microscopy or specific crystal analysis techniques
  • In practice = a combination of older woman + massive blood-tinged non-inflammatory effusion + destructive arthropathy with few osteophytes on X-ray (Kelley Ch.102, Kelley Ch.105)

Evaluation Tools

History

  • Older woman, shoulder pain, swelling, limited range of motion (Martinoli Ch.6)
  • History of recurrent large-volume joint aspiration, significant GH joint effusion volume (Kelley Ch.102)
  • Actively ask about: CKD / dialysis, trauma, joint overuse, neuropathy (Kelley Ch.49)

PE

  • Local pain, swelling (Martinoli Ch.6)
  • Varying degrees of limited joint range of motion (Martinoli Ch.6)
  • Joint instability (Martinoli Ch.6)
  • If the joint capsule has ruptured: diffuse swelling plus subcutaneous ecchymosis (Martinoli Ch.6)

X-ray

  • Advanced degenerative changes of the GH joint plus humeral head upward migration, reflecting a rotator cuff tear (Martinoli Ch.6)
  • Pseudoarthrosis between the humerus, coracoid, and acromion (Martinoli Ch.6)
  • Little osteophytosis, mild subchondral sclerosis; osteophytes are not a characteristic of Milwaukee shoulder (Martinoli Ch.6)
    • This “destructive arthropathy with sparse bone spurs” is also called atrophic degenerative arthritis and is a key distinguishing point from primary GH OA (Kelley Ch.102)
  • Calcific deposition visible in the inferolateral bursa (Martinoli Ch.6)
  • Overall imaging resembles neuropathy-like arthropathy with high-riding humeral head (Martinoli Ch.6)
  • Periarticular calcification and cuff rupture can also be seen (Kelley Ch.105)

Comparison Image

Martinoli Ch.6 Fig.6.140a-c is the most complete comparison image for this disease: ‘a’ is an AP X-ray showing upward migration of the humeral head, pseudoarthrosis between the humerus and coracoid/acromion, calcific deposition in the inferolateral bursa, and sparse bone spurs; ‘b’ is a coronal 12 to 5 MHz ultrasound showing extensive subdeltoid bursitis with synovial fronding and the bursa rupturing subcutaneously; ‘c’ is a clinical photo showing diffuse swelling and ecchymosis. The image is copyrighted and won’t be reproduced here.

Sono

  • Joint cavity is markedly distended, containing effusion plus echogenic debris (synovial hypertrophy and blood clots) (Martinoli Ch.6)
  • Calcific deposition, cartilage destruction, subchondral bone osteolysis (Martinoli Ch.6)
  • Extensive subdeltoid bursitis, synovium shows prominent synovial fronding, bursa rupturing subcutaneously can be seen (Martinoli Ch.6)
  • Important limitation: Ultrasound cannot reliably distinguish between MSS and the more common rotator cuff-related OA (Martinoli Ch.6)
  • Crystal echogenic characteristics help distinguish between BCP and CPPD (Kelley Ch.102)
    • BCP: Even if only 2 to 3 mm, presents as hypoechoic with posterior acoustic shadowing
    • CPPD: Presents a sparkling appearance, needs to be over 10 mm to produce posterior shadowing

Synovial Fluid Analysis

  • Appearance and volume: Massive effusion in the GH joint, often blood stained, high red blood cell content (Kelley Ch.102, Kelley Ch.105)
  • Cell count: non-inflammatory, at most only a relatively small amount of mononuclear cells (Kelley Ch.102)
  • Crystal identification, the most critical step for this disease
    • BCP and hydroxyapatite are globally nonbirefringent and cannot be seen under polarized light microscopy (Kelley Ch.102, Kelley Ch.56)
      • Aggregated particles only have edge birefringence (Kelley Ch.102)
    • Requires alizarin red S staining, looking for crystal clumps under a standard light microscope (Kelley Ch.56)
      • BCP stains strongly; CPP will also stain but stains weakly, and can be distinguished by this (Kelley Ch.102)
      • BCP is commonly seen within leukocytes as nonbirefringent spherical clumps (Kelley Ch.102, Mitra Ch.80)
    • Confirmatory level techniques: TEM, X-ray diffraction, Raman spectroscopy, FTIR, atomic force microscopy (Kelley Ch.102)
  • Send for Gram stain and culture simultaneously: The presence of crystals does not rule out infection, and crystals can also be detected in infected joints (Kelley Ch.102)

Classification

  • MSS and cuff tear arthropathy are often used synonymously in the literature (Kelley Ch.102, Kelley Ch.49)
  • The pathogenesis, classification, and treatment algorithm for cuff tear arthropathy were proposed by Seebauer et al., original source see Visotsky 2004
    • The textbook and guideline corpus used for these notes do not include the grading details of this classification, so it is temporarily not restated to avoid errors
  • Broad categorization: Belongs to the joint destructive manifestation of BCP (basic calcium phosphate) crystal deposition disease (Kelley Ch.102)

Differential Diagnosis

DiseaseKey distinguishing pointsSource
Primary glenohumeral OARotator cuff is usually intact, less bone erosion, less upward migration of humeral head; X-ray shows osteophytes, sclerosis, cysts; small effusion volumeKelley Ch.49
Septic arthritisMust be ruled out with Gram stain plus culture; positive for crystals does not rule out infectionKelley Ch.102
CPPD (pseudogout)CPP crystals are positively birefringent, rhomboid or rod-shaped; X-ray shows chondrocalcinosisKelley Ch.102
GoutMSU crystals are negatively birefringent needle-shaped; ultrasound shows double contour signMitra Ch.80, Kelley Ch.102
RA of shoulderInflammatory; involves periarticular structures plus subacromial bursitis plus cuff rupture; progressive loss of ROMKelley Ch.49
Neuropathic (Charcot) shoulderUnderlying neurological causes like syringomyelia, alcohol, diabetes, leprosyKelley Ch.102, Kelley Ch.49
Dialysis-related amyloid arthropathyβ2-microglobulin deposition; synovium markedly thickened with echoes, deep bone erosion; thickened heterogeneous cuffMartinoli Ch.6
Oxalate crystal depositionSeen in primary hyperoxaluria or long-term dialysis end-stage renal diseaseKelley Ch.102, ElMiedany Ch.7
Humeral head osteonecrosisHistory of fracture, steroids, or hemoglobinopathy; MRI is highly sensitive, crescent signKelley Ch.49
Synovial osteochondromatosis and rice bodiesUltrasound shows multiple nodules or filling defects in the bursaMartinoli Ch.6

Red Flags and Referral

  • When aspirating massive blood-tinged joint fluid, first rule out infection before talking about steroids, crystals and infection can coexist (Kelley Ch.102)
  • Fever, systemic symptoms, inflammatory synovial fluid (high white blood cells other than mononuclear cells) → follow the septic arthritis pathway (Kelley Ch.102)
  • Age under 55 or multi-joint crystal deposition → need to screen for primary metabolic or familial diseases (Kelley Ch.102)
  • Timing for orthopedic referral: Conservative treatment failure plus significant functional loss → evaluate for reverse shoulder arthroplasty (AAOS Rotator Cuff 2025, Consensus)
  • Advanced joint destruction → consider shoulder arthroplasty (Martinoli Ch.6)

Management

Management Algorithm

Decision axis = first rule out infection → symptom severity → response to aspiration and injection → degree of functional disability

Step 1: Joint aspiration and send for testing (mandatory)

  • Cell count and differential, alizarin red S crystal staining, Gram stain plus culture (Kelley Ch.102, Kelley Ch.56)
  • If results are inflammatory or culture is positive → follow infection pathway, no steroids

Step 2: First line after confirming non-infection

  • NSAIDs or selective COX-2 inhibitor (Kelley Ch.102 Table 102.6, Proven benefit)
  • Local steroid injection (Kelley Ch.102 Table 102.6, Proven benefit)
  • A single injection of steroid plus local anesthetic can offer short-term improvement in shoulder pain and function (AAOS Rotator Cuff 2025, Moderate)

Step 3: For recurrent effusion

  • Repeated joint aspiration plus intra-articular steroid injection is the mainstay of symptomatic treatment (Martinoli Ch.6)
  • Local irrigation (Kelley Ch.102 Table 102.6, Proven benefit)
  • Tidal irrigation might be beneficial for symptoms and function of MSS (Kelley Ch.102)

Step 4: Combined with BCP inflammation of the cuff or subacromial bursa

  • Needle aspiration plus irrigation plus steroid injection, ultrasound guidance can improve success rate (promotes calcification absorption) (Kelley Ch.102)
  • High-frequency therapeutic ultrasound to degrade BCP deposits (Kelley Ch.102 Table 102.6, Proven benefit)

Step 5: Conservative failure plus significant functional loss

  • Advanced disease consider shoulder arthroplasty (Martinoli Ch.6)
  • Hemiarthroplasty or reverse total shoulder arthroplasty (Kelley Ch.49; AAOS Rotator Cuff 2025, Consensus)

Warnings throughout the process

  • Multiple steroid injections may compromise rotator cuff integrity, affecting future repair (AAOS Rotator Cuff 2025, Limited)

Treatment Goals

  • Pain control, maintaining joint range of motion and function (Kelley Ch.49, Martinoli Ch.6)
  • The effusion itself requires repeated aspiration, so the treatment goal is on symptoms and function, not emptying the effusion all at once (Martinoli Ch.6)
  • Identify and treat correctable comorbidities: CPPD, chronic renal failure, hyperparathyroidism, hypomagnesemia (Kelley Ch.102, Mitra Ch.80)

Conservative Treatment

Joint Aspiration and Irrigation

  • Repeated arthrocentesis is the core step in treatment (Martinoli Ch.6)
  • Local irrigation is a proven benefit (Kelley Ch.102 Table 102.6)
  • Tidal irrigation is beneficial for MSS symptoms and function; there is no equivalent data for CPPD (Kelley Ch.102)

Medications

  • NSAIDs or selective COX-2 inhibitor, proven benefit (Kelley Ch.102 Table 102.6)
    • Must be extra conservative using NSAIDs in CKD 4; this is also why steroid injections are relatively attractive in this population
  • The principles of symptomatic treatment for BCP and pseudogout are similar: NSAIDs, intra-articular steroids, systemic steroids, ACTH, low-dose colchicine (Mitra Ch.80)
    • This is a general rule for CPPD and BCP; the specific evidence for MSS still primarily relies on aspiration plus local injection (Kelley Ch.102)

Local Steroid Injections

  • Intra-articular or local steroid injection is a proven benefit option for BCP crystal arthropathy (Kelley Ch.102 Table 102.6)
  • A single steroid injection combined with local anesthetic can be considered for short-term improvement in shoulder pain and function (AAOS Rotator Cuff 2025, Moderate)
    • High-quality studies show improvement in functional metrics at about 1.5 months post-injection, no longer significant after 4 months (AAOS Rotator Cuff 2025)
    • Those who cannot tolerate steroids might consider injectable NSAIDs (AAOS Rotator Cuff 2025, Moderate)
  • Precautions
    • Multiple injections might compromise cuff integrity, affecting subsequent repair (AAOS Rotator Cuff 2025, Limited)
    • Injecting close to the time of surgery might negatively affect the healing of a cuff repair (AAOS Rotator Cuff 2025)
    • Infection must be ruled out before injecting (Kelley Ch.102)

Steroid Injection Considerations for CKD Patients

  • CKD stage 4 is not a contraindication to intra-articular steroids, nor does it require dose adjustment based on renal function
    • The triamcinolone acetonide label has no dose reduction table for renal function, but notes it should be used with caution in renal insufficiency (cardio-renal effects) (FDA Triamcinolone Acetonide 2025)
    • Steroids in CKD generally do not require renal dose adjustment (Chen 2025)
    • Evidence: Moderate, label and nephrology prescription reviews align, no CKD-specific RCTs
  • The true risks are indirect, non-pharmacokinetic
    • Sodium and water retention, edema, potassium loss, and hypokalemic alkalosis; CKD’s compensatory excretory capacity is already limited (FDA Triamcinolone Acetonide 2025)
    • Hyperglycemia and hypertension induced by steroids independently contribute to renal function deterioration (Chen 2025)
    • Evidence: Low to moderate, mechanisms are clear but quantitative risk data is limited
  • The claim “it’s injected locally so it’s not absorbed” is invalid: Intra-articular steroids have clinically meaningful systemic absorption (Benzon 2025)
    • Blood sugar: Rises within hours, peaks around 6 to 32 hours, mostly returns to baseline in 3 to 7 days (Benzon 2025)
      • Knee joint injections are more likely to raise fasting and postprandial blood sugar than upper extremity injections (Benzon 2025)
    • HPA axis: Cortisol drops within hours, reaches nadir at 24 to 48 hours, mostly recovers in 1 to 4 weeks (Habib 2009)
    • A single 40 mg intrabursal triamcinolone or methylprednisolone injection can cause suppression measurable in urine lasting up to 45 days (Guaraldi 2019)
    • 2 to 4 weeks after a single knee joint methylprednisolone injection, up to 25% of patients show adrenal insufficiency on an ACTH stimulation test (Habib 2014)
    • Label: Triamcinolone acetonide is a long-acting formulation; adrenal suppression occurs 24 to 48 hours after a single dose and usually lasts 30 to 40 days (FDA Triamcinolone Acetonide 2025)
    • Evidence: Moderate, society guidelines and multiple small RCTs and pilots align
  • Renal insufficiency is actually one of the reasons to prefer intra-articular steroids: it avoids NSAIDs and colchicine (in gout scenarios) (Wechalekar 2013)
  • Practical checklist (when injecting in CKD 4)
    • Rule out infection before injecting
    • Monitor blood pressure, volume status, serum potassium after injection (Benzon 2025)
    • For those with diabetes or prediabetes, monitor blood sugar, especially days 1 to 7; hypoglycemic meds might need temporary adjustment (Benzon 2025)
    • Limit repeat injections, especially within 3 months; multi-joint or multiple injections will exacerbate and prolong systemic effects (Benzon 2025)
    • If surgery, trauma, or severe illness occurs within 2 months after injection, have a low threshold for testing for adrenal insufficiency (ESE-ES 2024)
    • The label suggests steroid coverage might still be needed under stress situations for up to a year (FDA Triamcinolone Acetonide 2025)

Physical Agents

  • High-frequency therapeutic ultrasound can degrade BCP crystal deposits, proven benefit (Kelley Ch.102 Table 102.6)
  • For BCP inflammation of the rotator cuff and subacromial bursa, ultrasound-guided techniques can promote calcification absorption (Kelley Ch.102)
  • Alternative therapies for GH OA (acupuncture, dry needling, TENS, glucosamine and chondroitin, capsaicin, cupping, etc.) have insufficient evidence to recommend for or against (AAOS Glenohumeral OA 2020, Consensus)

Surgery

Reverse Total Shoulder Arthroplasty (RSA)

  • After conservative treatment failure, for those with a massive unrepairable cuff tear combined with GH arthritis (i.e., cuff tear arthropathy), RSA can improve patient-reported outcomes (AAOS Rotator Cuff 2025, Consensus)
    • Evidence quality Low, belongs to working group consensus opinion (AAOS Rotator Cuff 2025)
  • Advanced MSS can consider shoulder arthroplasty (Martinoli Ch.6)

Hemiarthroplasty and Other Options

  • Hemiarthroplasty or reverse TSA might both be applicable for cuff tear arthropathy (Kelley Ch.49)
  • The functional outcome of an unconstrained prosthesis will be dragged down by bone erosion and cuff rupture (Kelley Ch.49)
  • For symptomatic but tolerable cases, arthroscopic débridement can occasionally be used to manage the cuff tear (Kelley Ch.49)

Post-op Rehabilitation

  • The corpus for these notes does not cover a specific RSA rehabilitation protocol; the general rehabilitation timeline after rotator cuff repair see Frontera Ch.17
  • Principles are the same as the conservative phase: protect the repair, gradually restore ROM and strength, needs to be coordinated with the surgeon based on tear size, location, and tissue quality (Frontera Ch.17)

Emerging Treatments

  • Phosphocitrate (a PPi analog) is a potent inhibitor of BCP crystal formation; it is a theoretic benefit and lacks clinical evidence (Kelley Ch.102 Table 102.6)
  • Drugs modulating ANKH or ENPP1 are also in the theoretical stage (Kelley Ch.102 Table 102.6)

Evidence × Setting Matrix

Intervention / SettingEvidenceConclusionPrimary Source
Repeated joint aspiration plus intra-articular steroid (MSS)Proven benefit (textbook level)Mainstay of symptomatic treatmentMartinoli Ch.6, Kelley Ch.102
Local irrigation and tidal irrigation (MSS)Proven benefit; tidal irrigation is beneficial for MSS, no equivalent data for CPPDConsider for recurrent effusionKelley Ch.102
High-frequency therapeutic ultrasound to degrade BCP depositsProven benefit (textbook level)Targets crystal depositionKelley Ch.102 Table 102.6
NSAIDs and COX-2 inhibitorProven benefitFirst-line medicationKelley Ch.102 Table 102.6
Single steroid plus local anesthetic injection (shoulder pain)Moderate (AAOS)Short-term improvement in pain and function, about 1.5 monthsAAOS Rotator Cuff 2025
Multiple steroid injectionsLimited (AAOS)Might compromise cuff integrity, affecting repairAAOS Rotator Cuff 2025
Intra-articular steroid × CKD 4ModerateNot contraindicated, no dose reduction based on renal function; risks are sodium/water retention, blood sugar, HPA suppressionFDA Triamcinolone Acetonide 2025, Chen 2025, Benzon 2025
Reverse shoulder arthroplasty (cuff tear arthropathy)Consensus / Low quality (AAOS)Only consider after conservative failure plus significant functional lossAAOS Rotator Cuff 2025
Phosphocitrate, ANKH and ENPP1 modulationTheoretic onlyNo clinical evidence yetKelley Ch.102 Table 102.6

Glossary

AbbreviationFull Name
MSSMilwaukee shoulder syndrome
BCPbasic calcium phosphate
HAhydroxyapatite
CPPDcalcium pyrophosphate dihydrate deposition disease
PPiinorganic pyrophosphate
GHglenohumeral
RSAreverse total shoulder arthroplasty
CKDchronic kidney disease
HPAhypothalamic-pituitary-adrenal (axis)
ACTHadrenocorticotropic hormone

Note Production Workflow

This note was made using the textbook-to-note workflow: I toss a topic in, and Claude goes through the 250+ PM&R and rheumatology textbooks converted to markdown and 77 society guidelines on my computer. It writes the notes following a fixed disease template, ensuring every sentence is backed by a source, and finally runs a machine audit script to check the formatting and citations.

Two processing details from this run:

I only search externally for what the textbooks don’t cover. The safety of intra-articular steroids in CKD stage 4 isn’t directly discussed in the PM&R and rheumatology textbooks I have, so I ran OpenEvidence for that section. I cross-checked all six primary cited DOIs with Crossref once to confirm the articles exist and the titles match.

During the process, I threw out two pieces of data: one applied risk numbers from the inflammatory bowel disease population to this scenario, which was a mismatched population; the other was from two queries that gave contradictory percentages (25% vs. 52%) for “adrenal insufficiency after a single injection.” I kept the one with a clear randomized controlled trial source. These trade-offs are documented in the notes, not just silently removed.

The quality control gate for image extraction only caught an error because of manual review this time. I wanted to pull Fig.6.140a-c from an ultrasound textbook. The tool’s QC reported “pass,” but when I actually opened the image file, the content was a different MRI image—the image file index was misaligned. Just because the machine says it passed doesn’t mean the content is right. In the end, I had to re-render the image area from the original PDF and manually verify the caption to get the correct image. That image is copyrighted and is only kept in my vault, not posted here.

If you also have a Claude or Codex subscription, you can hand off this kind of mechanical labor of verification and compilation to them, leaving the judgment to yourself. You can start with Getting started with AI: Installation and first steps and How to talk to AI agents, and my other tools are compiled in My AI toolbox.

If there are any misunderstandings, corrections are welcome.

Reference

Books

  • Kelley Ch.49 / Ch.56 / Ch.102 / Ch.105 — Firestein & Kelley’s Textbook of Rheumatology, 11e, 2021
  • Martinoli Ch.6 — Bianchi S, Martinoli C. Ultrasound of the Musculoskeletal System, 1e, 2007
  • ElMiedany Ch.7 — El Miedany Y. Musculoskeletal Ultrasonography in Rheumatic Diseases, 1e, 2015
  • Mitra Ch.80 — Mitra R. Principles of Rehabilitation Medicine, 1e, 2019
  • Frontera Ch.17 — Frontera WR. Essentials of Physical Medicine and Rehabilitation, 4e, 2019

Guidelines

  • AAOS 2025 — Management of Rotator Cuff Injuries CPG, American Academy of Orthopaedic Surgeons, 2025
  • AAOS 2020 — Management of Glenohumeral Joint Osteoarthritis CPG, American Academy of Orthopaedic Surgeons, 2020
  • Benzon 2025 — Benzon HT, Provenzano DA, Nagpal A, et al. Use and Safety of Corticosteroid Injections in Joints and Musculoskeletal Soft Tissue: Guidelines From ASRA, AAPM, ASIPP and IPSIS. Reg Anesth Pain Med. 2025. doi:10.1136/rapm-2024-105656. PMID: 40015722
  • ESE-ES 2024 — Beuschlein F, Else T, Bancos I, et al. European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and Therapy of Glucocorticoid-Induced Adrenal Insufficiency. J Clin Endocrinol Metab. 2024. doi:10.1210/clinem/dgae250. PMID: 38724043
  • FDA 2025 — Triamcinolone Acetonide injectable suspension, US FDA prescribing information, label revision 2025-04-15

Papers

  • Garancis 1981 — Garancis JC, Cheung HS, Halverson PB, et al. Arthritis Rheum. 1981;24:484-491
  • Halverson 1990 — Halverson PB, Carrera GF, McCarty DJ. Arch Intern Med. 1990;150:677
  • McCarty 1989 — McCarty DJ. J Rheumatol. 1989;32:668
  • Visotsky 2004 — Visotsky JL, Basamania C, Seebauer L, et al. J Bone Joint Surg Am. 2004;86-A(suppl 2):35-40
  • Chen 2025 — Chen L, Srinivasan A, Choy SW, et al. Aliment Pharmacol Ther. 2025;62(3). PMID: 40601470
  • Guaraldi 2019 — Guaraldi F, Gori D, Calderoni P, et al. J Endocrinol Invest. 2019;42(9). PMID: 30877658
  • Habib 2009 — Habib GS. Clin Rheumatol. 2009;28(7). PMID: 19252817
  • Habib 2014 — Habib G, Jabbour A, Artul S, Hakim G. Clin Rheumatol. 2014;33(1). PMID: 23982564
  • Wechalekar 2013 — Wechalekar MD, Vinik O, Schlesinger N, Buchbinder R. Cochrane Database Syst Rev. 2013. PMID: 23633379
  • Wortmann 1991 — Wortmann RL, Veum JA, Rachow JW. Arthritis Rheum. 1991;34:1014